Advanced Pharmaceutical Bulletin

Advanced Pharmaceutical Bulletin is a quarterly fully open access journal of the pharmaceutical sciences published by TUOMS PRESS, the imprint of Tabriz University of Medical Sciences, and the official journal of its Drug Applied Research Center and Faculty of Pharmacy. Founded in 2011, it carries a 2025 Journal Impact Factor of 4.7.《先进药学通报》（Advanced Pharmaceutical Bulletin）是大不里士医科大学（Tabriz University of Medical Sciences）出版机构（TUOMS PRESS）出版的药学领域季刊完全开放获取期刊，也是该校药物应用研究中心与药学院的官方刊物，2011 年创刊，2025 年影响因子为 4.7。

Scope

• The journal publishes original research papers, scientific commentaries, views, review articles and editorial commentary across a wide range of integrative fields within the pharmaceutical sciences.该刊发表原创研究论文、科学评论、观点、综述文章与编辑评论，覆盖药学领域广泛的综合性方向。

• Its focus is on concepts in pharmaceutical science, covering the physical, chemical, biological, clinical and regulatory aspects of the discipline.其重心在药学的基本概念，涵盖该学科的物理、化学、生物、临床与监管诸方面。

• Pharmacokinetics, biopharmaceutics and pharmacodynamics sit at the centre of the scope.药代动力学、生物药剂学与药效动力学处于收稿范围的核心位置。

• Pro-drug development, the metabolic disposition of bioactive agents and dosage form design are regularly covered.前药开发、活性药物的代谢处置与制剂设计是常设主题。

• Immune-pharmaceuticals and the chemistry and biotechnology of proteins and peptides are included, in so far as these bear on pharmaceutical technology.免疫药物以及蛋白与多肽的化学与生物技术也在其列，前提是这些内容与药剂技术相关。

• Gene delivery and targeted drug delivery using nanotechnology form a distinct line of work within the journal.基因递送与借助纳米技术的靶向药物递送构成该刊一条独立的研究脉络。

• The editors set firm limits, excluding routine bioequivalence studies, formulation work that merely applies known techniques to another drug, and natural product papers reporting only the pharmacological data of a plant.编辑部划定了明确边界，不收常规的生物等效性研究，不收只是把已有制剂技术换一种药物套用的文章，也不收仅报告某植物药理数据的天然产物论文。

History

• The journal was founded in 2011 as the official publication of the Drug Applied Research Center and the Faculty of Pharmacy of Tabriz University of Medical Sciences.该刊 2011 年创刊，作为大不里士医科大学药物应用研究中心与药学院的官方出版物。

• It has been published under the TUOMS PRESS imprint of the university from the outset, and by 2026 it had reached volume 16 with four issues a year.自创刊起即以该校的（TUOMS PRESS）为出版机构署名，到 2026 年已出至第 16 卷，每年 4 期。

• It has been fully open access from the beginning, it is listed in the Directory of Open Access Journals, and it charges neither submission fees nor article processing charges, the cost being subsidised by the university.该刊自创刊起即为完全开放获取，并被（DOAJ）收录，既不收投稿费也不收文章处理费，费用由该校补贴。

• Articles are published under a Creative Commons Attribution 4.0 licence with the copyright retained by the authors, and deposited in PubMed Central.文章采用（Creative Commons Attribution 4.0）许可发表，著作权由作者保留，全部论文存入（PubMed Central）。

• Its running issue concept means accepted manuscripts appear without waiting for the next numbered issue, a feature the journal presents as a benefit to authors.该刊采用连续出版的方式，录用稿件无需等待下一期编号即可上线，这也是该刊向作者推介的卖点。

• The journal is indexed in the Emerging Sources Citation Index, Scopus, PubMed, PubMed Central, EMBASE and the Chemical Abstracts Service, and its 2025 Journal Impact Factor of 4.7 follows 4.1 in 2024.该刊被（ESCI）、（Scopus）、（PubMed）、（PubMed Central）、（EMBASE）与（CAS）收录，2025 年影响因子 4.7，2024 年为 4.1。

Editors

• The founder and Editor-in-Chief is Hadi Valizadeh, Professor of Pharmaceutics at the Faculty of Pharmacy of Tabriz University of Medical Sciences, working on pharmaceutics and drug delivery.创刊主编是（Hadi Valizadeh），大不里士医科大学药学院药剂学教授，研究方向为药剂学与药物递送。

• The associate editors include Parvin Zakeri-Milani of the same faculty, the pharmacologist Hossein Babaei, the stem cell biologist Hojjatollah Nozad Charoudeh and the pharmaceutical nanotechnologist Jafar Ezzati Nazhad Dolatabadi.副编辑包括同学院的（Parvin Zakeri-Milani）、药理学家（Hossein Babaei）、干细胞生物学家（Hojjatollah Nozad Charoudeh），以及药剂纳米技术学者（Jafar Ezzati Nazhad Dolatabadi）。

• Editors drawn from abroad include Gaetano Santulli of the Albert Einstein College of Medicine, Velid Unsal of Mardin Artuklu University and Mostafa Akbarzadeh-Khiavi of the Liver and Gastrointestinal Diseases Research Center in Tabriz.来自海外的编辑包括（Albert Einstein College of Medicine）的（Gaetano Santulli）、土耳其马尔丁阿特库卢大学的（Velid Unsal），以及大不里士肝脏与胃肠疾病研究中心的（Mostafa Akbarzadeh-Khiavi）。

• An international editorial and advisory board of about twenty further members is drawn from ten countries, among them Raimar Loebenberg of the University of Alberta, Gabriele Caviglioli of Genoa, Miguel de la Guardia of Valencia, Ali Nokhodchi of Sussex, Saurabh Bhatia of Amity University and Khaled Nabih Zaki Rashed of the National Research Centre in Egypt.国际编辑与顾问委员会另有约 20 名成员，来自 10 个国家，其中有阿尔伯塔大学的（Raimar Loebenberg）、热那亚大学的（Gabriele Caviglioli）、巴伦西亚大学的（Miguel de la Guardia）、萨塞克斯大学的（Ali Nokhodchi），以及埃及国家研究中心的（Khaled Nabih Zaki Rashed）。

• All submitted manuscripts go through a double blind review process, usually handled by two reviewers chosen by the editor, and the Editor-in-Chief or the associate editors decide.所有投稿一律实行双盲评审，通常由主编指派两位审稿人，稿件最终决定由主编或副编辑作出。

• Manuscripts written by members of the editorial team are handled by editors unaffiliated with the author, and editorials and obituaries written by the journal's own editors are not sent out for external review.编辑团队成员撰写的稿件交由与作者无隶属关系的编辑处理，编辑本人撰写的社论与纪念文字不经外审。